Iterum Therapeutics Focused On First Oral Penem
Executive Summary
Emerging Company Profile: Iterum Therapeutics is developing a Phase III-ready penem antibiotic, sulopenem, which could be the first in its class to be administered orally. It’s the second foray into setting up an anti-infectives-focused company by a team of experienced biotech executives and entrepreneurs that previously took Durata’s dalbavancin through clinical development.
You may also be interested in...
QIDP Roundup: Familiar Names Dominate 2019 Designations
US FDA's Qualified Infectious Disease Product program is growing slowly, but still growing.
German Government Joins Superbug Fight With €40m CARB-X Investment
Germany’s Ministry of Education and Research has pledged €40m over four years to the antibacterial accelerator CARB-X, part of an overall €500m the country has committed to fighting superbugs in the next decade.
QIDP Program Heads Into Uncomplicated Territory: Iterum, Paratek Eye uUTI Indications
Iterum’ssulopenem is first QIDP candidate to enter Phase III for uncomplicated urinary tract infection; Paratek’sNuzyra could be next.